How to Get Repatha (Evolocumab) in Rhode Island

What Is Repatha and Why Would a Rhode Island Clinician Prescribe It?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more receptors available to clear LDL-C from the bloodstream. The FDA approved evolocumab in August 2015 for adults with heterozygous or homozygous familial hypercholesterolemia (FH) and for adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The FOURIER trial (N=27,564) assigned patients with established ASCVD and LDL-C of 70 mg/dL or higher on optimized statin therapy to evolocumab 140 mg every two weeks or 420 mg monthly versus placebo. At 48 weeks, evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL (P<0.001). The primary composite endpoint of cardiovascular death, MI, stroke, unstable angina hospitalization, or coronary revascularization fell by 15% over a median follow-up of 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [2].

The 2022 ACC/AHA Cholesterol Guideline states: "For patients with very high-risk ASCVD who require additional LDL-C lowering despite maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor is recommended" [3]. Rhode Island clinicians prescribing in line with these guidelines have a clear evidence base to support the prescription.

Rhode Island Telehealth Rules and Repatha Prescribing

Rhode Island authorizes telehealth prescribing for non-controlled medications. Evolocumab is not a controlled substance, so a licensed prescriber who establishes a valid patient-provider relationship via synchronous video can legally issue a Repatha prescription to a Rhode Island resident [4].

Telehealth works. A prescriber must still collect a thorough cardiovascular history, review labs, and document a diagnosis of FH or ASCVD before writing the order. The Rhode Island Department of Health aligns with the Interstate Medical Licensure Compact (IMLC), meaning out-of-state physicians licensed in Rhode Island through the Compact can prescribe to RI patients using telehealth [5].

For patients new to evolocumab, the telehealth visit typically covers review of statin history (dose and duration), a current fasting lipid panel, LFTs, and relevant cardiac history such as prior MI, PCI, or CABG. The prescriber documents medical necessity in the chart, which doubles as the foundation for a prior authorization submission. Expect the initial telehealth consultation to run 20 to 40 minutes.

HealthRX clinicians licensed in Rhode Island can initiate this process entirely online. After the visit, the prescription is sent electronically to a specialty pharmacy or a licensed RI retail pharmacy, and prior authorization paperwork begins the same day.

Labs Required Before Starting Repatha in Rhode Island

Most Rhode Island insurers, including Blue Cross Blue Shield of Rhode Island and Neighborhood Health Plan of Rhode Island (Medicaid MCO), ask for documented lab values as part of the prior authorization packet [6].

The standard panel includes fasting lipid panel (total cholesterol, LDL-C, HDL-C, non-HDL-C, triglycerides), hepatic function tests (AST, ALT, total bilirubin), TSH to rule out secondary dyslipidemia, and fasting glucose or HbA1c if diabetes status is unknown. Some plans additionally request a lipoprotein(a) value if FH is the stated diagnosis, because elevated Lp(a) strengthens medical necessity documentation [7].

Labs should be no older than 90 days at the time of PA submission. A fasting lipid panel drawn the morning of the telehealth visit satisfies most insurer timelines. If prior statin intolerance is a factor in the request, the chart must include documentation of the statin trial, dose used, duration, and the adverse effect that led to discontinuation.

The European Atherosclerosis Society consensus statement notes that an LDL-C of 100 mg/dL or higher on maximally tolerated therapy in an ASCVD patient provides a clear indication for PCSK9 inhibitor therapy, a threshold many RI plans echo in their PA criteria [8].

Prior Authorization in Rhode Island: Step-by-Step

Prior authorization is the main barrier to Repatha access in Rhode Island. Nearly all commercial carriers and Rhode Island Medicaid require it. Here is the sequence a patient and prescriber work through together.

Step 1. Document the qualifying diagnosis. The prescriber charts either established ASCVD (ICD-10: I25.10, I21.x, I63.x, or similar) or FH (ICD-10: E78.01 for heterozygous, E78.02 for homozygous). Rhode Island Medicaid covers both indications with PA [9].

Step 2. Show statin optimization. Most RI plans require evidence of a trial of high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) for at least 90 days, unless contraindicated. If statin intolerance is documented, the plan may waive this step after reviewing chart notes.

Step 3. Attach current labs. Include the fasting lipid panel showing LDL-C at or above the plan's threshold (commonly 70 mg/dL for ASCVD or 100 mg/dL for primary prevention FH).

Step 4. Submit the PA form. Specialty pharmacies handling Repatha (such as CVS Specialty, Walgreens Specialty, and Accredo) routinely manage PA submissions on behalf of the prescriber. The PA form for Rhode Island Medicaid is submitted through the RIPAE portal or through the relevant MCO's online system [9].

Step 5. Peer-to-peer review if denied. A first-line denial is not the end. Rhode Island carriers must offer a peer-to-peer review within a reasonable timeframe. The prescriber speaks with the plan's medical director, presents the clinical rationale, and a significant portion of initial denials are overturned at this stage.

The ACC's 2017 PCSK9 inhibitor Expert Consensus Decision Pathway states: "Clinicians should carefully document the clinical rationale for PCSK9 inhibitor therapy, including the patient's cardiovascular risk category, prior lipid-lowering therapy, and LDL-C response, to support coverage determinations" [10].

Manufacturer Patient Assistance and Copay Programs

Amgen operates the Repatha SupportPlus program for commercially insured patients who meet income criteria [11]. Eligible patients pay as little as $0 per month under the copay card program. Income limits and eligibility rules change periodically, so patients should verify current terms at Amgen's official site or by calling the SupportPlus line directly.

Uninsured Rhode Island residents or those whose plans deny coverage after appeal may qualify for Amgen's patient assistance program (PAP), which provides Repatha at no cost to patients whose household income falls below a defined threshold. The prescriber completes a one-page enrollment form, and Amgen ships the medication directly to the patient's home [11].

Rhode Island Medicaid patients who receive approval through the PA process pay no out-of-pocket cost for the medication itself, though any specialist visit copays apply separately.

Pharmacy Options in Rhode Island for Repatha

Repatha is a specialty biologic, so most retail pharmacies do not stock it on the shelf. Filling a Repatha prescription in Rhode Island generally goes through one of three channels.

Specialty pharmacy mail-order. CVS Specialty, Walgreens Specialty (AllianceRx), Accredo (Express Scripts), and Optum Specialty Pharmacy all ship to Rhode Island addresses. Typical delivery after PA approval is 3 to 7 business days. Repatha must be shipped cold (2 to 8 degrees Celsius) and may be stored at room temperature for up to 30 days after removal from refrigeration according to the FDA-approved labeling [1].

Local specialty-capable retail pharmacies. Several independent and chain pharmacies in Providence, Warwick, and Cranston can order Repatha through AmerisourceBergen or McKesson specialty distribution channels. Confirm cold-chain handling capability before requesting a local fill.

503A compounding pharmacies. Licensed 503A pharmacies in Rhode Island may compound evolocumab-based preparations for patients with a valid individual prescription. Patients should verify that the compounding pharmacy holds a current Rhode Island Board of Pharmacy license and that the compounder has appropriate sterile-manufacturing accreditation (USP 797 compliance) before use [12]. Compounded biologics carry different regulatory standing than the FDA-approved Repatha product.

Transferring an Existing Repatha Prescription to Rhode Island

Patients relocating to Rhode Island who already have a Repatha prescription from another state face a straightforward but sometimes slow process.

A specialty pharmacy can transfer the prescription if the prescribing provider is licensed in Rhode Island or if a new Rhode Island-licensed provider assumes care. If the original prescriber is not licensed in RI, the easiest path is a telehealth follow-up with a Rhode Island-licensed clinician who reviews the chart, confirms the diagnosis and current labs, and issues a new prescription [13]. Rhode Island does not require an in-person visit for a non-controlled medication refill, so this handoff can happen within a single business day.

Patients on Amgen's SupportPlus copay card can carry the card to a new specialty pharmacy in Rhode Island without re-enrolling, as the program is pharmacy-agnostic as long as the dispensing pharmacy is a participating SupportPlus network pharmacy [11].

Who Can Prescribe Repatha in Rhode Island?

Rhode Island law permits prescriptive authority for evolocumab across multiple license types. Physicians (MD and DO), nurse practitioners (NP) with full practice authority under Rhode Island law, and physician assistants (PA) with a collaborative agreement can all write a valid prescription for Repatha [14].

Rhode Island NPs hold full practice authority. They do not require a physician collaborator to prescribe non-controlled medications, making NP-led telehealth practices fully equipped to manage Repatha prescribing independently. This expands access considerably, particularly in underserved areas of the state.

Dentists, pharmacists (in clinical pharmacist practitioner roles), and certified nurse-midwives do not have standard authority to prescribe cardiovascular biologics in Rhode Island without additional collaborative agreements.

Dosing, Injection Technique, and Storage

The FDA-approved dosing options are 140 mg subcutaneously every two weeks (single autoinjector pen or prefilled syringe) or 420 mg subcutaneously once monthly administered as three consecutive 140 mg injections within 30 minutes, or using the Pushtronex on-body infusion device [1].

Injection sites include the abdomen, thigh, or upper arm. Rotate sites with each injection. Remove the device from the refrigerator 30 minutes before use to allow it to reach room temperature, which reduces injection-site discomfort. Do not inject into skin that is bruised, tender, red, or indurated [1].

The DESCARTES trial (N=901) assessed 52-week evolocumab therapy on background statin and found a mean LDL-C reduction of 57.0% compared with placebo (P<0.001), with a safety profile comparable to placebo and no meaningful increase in neurocognitive adverse events [15]. A subsequent Cochrane review of PCSK9 inhibitor trials (74 RCTs, N=79,578) confirmed significant reductions in all-cause mortality (OR 0.86 to 95% CI 0.79 to 0.93) and non-fatal MI (OR 0.72 to 95% CI 0.66 to 0.79) [16].

Patients with homozygous FH may require more intensive dosing adjustments or adjunctive LDL apheresis; an FH specialist referral is appropriate in those cases [17].

Monitoring After Starting Repatha

After the first injection, schedule a fasting lipid panel at 4 to 8 weeks to confirm LDL-C response. A reduction of 50 to 60% from baseline is expected in most patients [2]. If the response is lower, assess injection technique, confirm the medication was stored properly, and review adherence.

Hepatic function testing is not required on a fixed schedule with evolocumab, unlike older lipid therapies. The FOURIER trial found no significant difference in liver enzyme elevations between the evolocumab and placebo groups (ALT or AST greater than three times the upper limit of normal: 1.5% vs. 1.4%) [2].

Annual lipid panels thereafter are standard of care under ACC/AHA guidelines. Rhode Island providers following the 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease should target an LDL-C below 70 mg/dL in very-high-risk patients and below 55 mg/dL in certain extreme-risk populations, such as those with a second major ASCVD event within two years [3].

Cost and Insurance Coverage in Rhode Island

Repatha's list price is approximately $5,850 per year with the current Amgen net pricing agreements, though actual insurer-negotiated rates are lower [11]. Commercially insured patients with access to the Amgen copay card may pay $0 to $30 per month out of pocket.

Rhode Island Medicaid (RIte Care, Neighborhood, and UnitedHealthcare Community Plan of Rhode Island) covers Repatha under the pharmacy benefit with a prior authorization [9]. Approved PA periods are typically 12 months, after which a re-authorization request documents continued clinical benefit (confirmed LDL-C reduction and no major adverse events).

Medicare Part D plans vary. Some Rhode Island Part D formularies place evolocumab on Tier 4 or Tier 5. Patients on Medicare should request a formulary exception citing the clinical necessity documentation, which may reduce the tier or cost-sharing significantly. The Medicare Extra Help (Low Income Subsidy) program covers a substantial portion of specialty drug costs for qualifying Rhode Island beneficiaries [18].